PCSK9 and hyperlipidemia: PCSK9 inhibitors have been shown to not only reduce low-density lipoprotein (LDL) cholesterol levels in patients with hyperlipidaemia [4–6], but also lower the risk of cardiovascular events in patients with established cardiovascular disease [7, 8].